Although acute renal graft rejection rate has declined in the last years, and because an
adequate therapy can improve graft outcome, its therapy remains as one of the most …

Introduction Antibody-mediated rejection (ABMR) is a leading cause of kidney allograft
failure. Its therapy continues to be challenge, and no treatment has been approved for the …

Acute antibody-mediated rejection (AMR), also termed acute humoral rejection, remains one
of the most challenging clinical events in kidney transplantation. This clinicopathologic entity …

Despite significant advancements in immunosuppressive therapies, kidney transplant
rejection continues to pose a substantial challenge, impacting the long-term survival of …

Background. We performed a comprehensive systematic review to determine the relative
benefits and harms of widely used interventions used to treat acute rejection in kidney …

Background Antibody-mediated rejection (AMR) is a recognized cause of allograft loss in
kidney transplant recipients. A range of therapies targeting removal of circulating donor …

(MMF) for kidney transplantation in 1995, the primary endpoint for transplant
immunosuppressant drug development has been “treatment failure” or “efficacy failure,” …

Background Current treatments for antibody-mediated rejection (AMR) in kidney
transplantation are based on low-quality data from a small number of controlled trials. Novel …

Progress in transplantation therapeutics requires validation from multicenter trials in which
enrollment criteria and endpoint definitions have been standardized. A database of acute …

Advances in immunosuppressive therapy have drastically improved acute rejection rates in
kidney transplant recipients over the past five decades. Nevertheless, it should remain high …